Graham Capital Management’s Myriad Genetics MYGN Stock Holding History

Graham Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164K	Sell	28,804 -32,676	-53%	-$148K	﹤0.01%	1077
2026 Q1	$277K	Buy	61,480 +31,383	+104%	+$164K	0.01%	847
2025 Q4	$185K	Buy	+30,097	New	+$218K	﹤0.01%	1065
2025 Q2	–	Sell	-71,349	Closed	-$633K	–	1497
2025 Q1	$633K	Buy	+71,349	New	+$857K	0.01%	713
2024 Q4	–	Sell	-43,203	Closed	-$1.18M	–	1394
2024 Q3	$1.18M	Buy	43,203 +26,850	+164%	+$727K	0.02%	416
2024 Q2	$400K	Buy	+16,353	New	+$359K	0.01%	656
2023 Q3	–	Sell	-8,815	Closed	-$204K	–	1198
2023 Q2	$204K	Buy	+8,815	New	+$192K	0.01%	812

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Graham Capital Management's MYGN Position: Q2 2026 in Review

Graham Capital Management reduced its Myriad Genetics (MYGN) stake by 53% in Q2 2026, selling an estimated $148K and leaving 28,804 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #1077.

Graham Capital Management first reported a position in MYGN in Q2 2023 and has held it in 7 quarters since. The position peaked at $1.18M in Q3 2024. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Graham Capital Management held 28,804 shares of Myriad Genetics worth $164K as of Q2 2026.
Graham Capital Management sold 32,676 Myriad Genetics shares in Q2 2026, an estimated $148K.
Myriad Genetics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1077 holding.
Graham Capital Management first reported a position in Myriad Genetics in Q2 2023 and has held it in 7 quarters since.
Graham Capital Management's Myriad Genetics position peaked at $1.18M in Q3 2024.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.